Abstracts tagged "T cells and interleukins (IL)"

Abstract Number: 1795 • 2017 ACR/ARHP Annual Meeting
IL-7 in Primary Sjogren Syndrome (pSS) Is Secreted By Salivary Gland Epithelial Cells after IFN Stimulation and Is Associated with B-Cell Activation
Alexandre Virone¹, Juliette Pascaud², Elodie Rivière¹, Jacques-Eric Gottenberg³, Véronique Le Guern⁴, Xavier Mariette¹ and Gaetane Nocturne⁵, ¹Université Paris Sud, Paris, France, ²U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ³CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France
Background/Purpose : pSS is characterized by a strong IFN signature, ectopic germinal centers formation and a chronic blood lymphopenia. IL-7 plays a central part in…
Abstract Number: 2737 • 2014 ACR/ARHP Annual Meeting
Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus
Tue K. Rasmussen¹, Thomas Andersen¹, Rasmus Bak¹, Gloria Yiu², Kristian Steengaard-Petersen³, Jacob G. Mikkelsen¹, Paul J. Utz⁴, Christian Holm¹ and Bent Deleuran^3,5, ¹Department of Biomedicine, Aarhus University, Aarhus C, Denmark, ²Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Department of Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose IL-21 is a key regulator of B cells functions and autoantibody production and is mainly produced by follicular T helper cells. The purpose of…
Abstract Number: 510 • 2012 ACR/ARHP Annual Meeting
IL-7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7-Induced B Cell Activation in Primary Sjögren’s Syndrome
A. Bikker¹, C.R. Willis², A.a. Kruize¹, J.W.J. Bijlsma³, F.P.J.G. Lafeber³ and J.A.G. van Roon⁴, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Amgen Inc., Seattle, WA, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Toll-like receptors (TLRs) are involved in the recognition of nucleic acids (viral, bacterial, and possibly self) and have been implicated in several auto-immune diseases.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].